Jaguar Health Inc (JAGX) Share Price

What your plan Shadow? You are/were a big supporter, do you think the data is good? Any chances of recovery or it’s just another ?

This CEO needs to be investigated. The RS was BS, the "imminent" publishing of data??? These have totally screwed the shareholder, and she damn well knew exactly what was happening, or this thing would have been sub penny.

For sure not a good stock at all unless around 5 cents then I can play with it. Free ATM for the CEO all they do offering dumping and RS

I was owning shares. 75% down.

Data was GOOD, as I predicted. Can't blame my own DD

Can blame management. Wtf was that for a shit show. No complete data, horrible press release. Horrible managed

I really don't think Shadow ever owned any shares. He was just here to spout lies about the results and try to get the last drop of money out of the remaining unsuspected shareholders....koddos to you shadow. Great job. This will be back to 5 cents again in no time... Another offering , another reverse split maybe they'll change their name to TIGX... Same criminals , same outcome. CEO waited till now because she's leaving for her European trip and Africa trip tomorrow. She just wanted to get the frig out of Dodge before the death threats started.

Me too. They try and BS everyone with the “we have to do this to stay in the nasdaq”. That kills the shareholder especially when like you said, it will be at a nickel again soon. Glad I got out as soon as I heard anything about a reverse split and how good it was going to be for the company and shareholders. Not even good for the company because no one has faith or trust in the controlling interests anymore.

lol idiot

right lol .... big redddddd

right lol .....

mr brains how is your account????
i knowwww biggggg redddddd

look at the pps i told you idiots

JAGX new 52 week low

So happy I got out before RS this junk one so dead years ago but I will buy some when it drops to 5 cents which it’s coming soon

Mayday!!!!

Yes, after the next reverse split! LOL

Yes, after the next reverse split! LOL

I got out while I was ahead pre-split, and she is Definitely Not My CEO!!! LOL You must have me confused with someone else???

With that said I was really hoping for the ones who went through the reverse split here could have gotten paid and not had their cakes taken by this CEO Twice!

Do you still see 10$ coming??

I have no words. Only bad, horrible ones, that are unspeakable.

They will continue to dilute and next year will probably do another massive reverse split. I was really hoping for the current shareholders that this study would have come out positive and that this could have seen some very nice gains.

ShadowDiviner is speechless.....We waited 5 years for this ....omfg... So CEO JUST OUTRIGHT LIED ? Cmon back and defend your great CEO.....what an absolute azzfuc

Holy Crap? What happened here???

Yea, I guess I am confused. After reading through the results, it sounds like the subgroups did see market improvements. So, to me it sounds like positive news. However it did not meet all their expectations.

What was everyone else's take away?

this was not supposed to cure cancer or shrink tumors - they made it sound like a failure

Picking up some shares down here

Subgroup patients comprised of 75% of the trial - Lung and breast meaningful and relevant

Did NOT meet its end point.. wow..

https://archive.fast-edgar.com/20240723/ATB2M62C8Z22SZZ222ZG2ZZZI5GSH2S2D26G/tm2419925d1_ex99-1.htm

SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced the results from its initial analysis of the pivotal Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy. Crofelemer is an FDA-approved prescription drug for the symptomatic relief of diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy. The initial results from the OnTarget study show that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types in the trial.

“While the results of the OnTarget study did not achieve significance for all tumor types receiving various targeted therapies, I am pleased that the subgroup analyses show that crofelemer provides clinically meaningful improvement in the prespecified subgroups of breast and respiratory tumor patients. Clinical meaningfulness of these results is based on the information provided by solid tumor patients from a survey that informed us about the appropriate clinical study design and clinical endpoints, that are important to the patients in this prophylactic trial. We will continue to evaluate important OnTarget findings, with further analyses,” said Pablo Okhuysen, MD, Professor of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, who is the Principal Investigator of the OnTarget clinical trial. “It is important to note that the prespecified secondary outcomes for this study were based on outcomes that were considered to be meaningful by patients experiencing diarrhea due to targeted therapy.”

KEY TAKE-A-WAYS FROM ONTARGET TRIAL

· Unprecedented OnTarget trial included patients with 10 different tumor types and 24 different targeted agents, with and without multiple standard cytotoxic chemotherapies.
· Study did not meet prespecified analysis of primary endpoint for all tumor types.
· Analysis did reveal clinically relevant signals for patients in the prespecified subgroups of breast and respiratory cancers, including lung cancer, who received targeted therapies. These subgroups of patients comprised over 75% of the patients in the trial.
· Breast and lung cancers are two of the three most common cancers, with patients often remaining on targeted therapy over prolonged periods.
· A growing and urgent unmet medical need exists for novel non-opioid chronic agents to treat CTD.
· Results indicate positive signals improved over the initial 12-week phase of study; data for additional 12-week extension phase yet to be analyzed.
· Company expects to engage with FDA after full review of data.

It should be MANDATORY that companies post the PR on their website the

instant its released.

IF I could see the PR, this could be a potential 'deal'

Wonder whats driving the sell off??

Shorts are ready to take it down

Stock is going to 1.00

People got scared maybe?

No PR on their website.

can't find any PR?? but volume activity has really picked up since 8

Not that I can see

guessing something was just 'released'??

Not a lot of folks 'paying' attention this morning based on the volume activity..

Going to be interesting to see what the company says if anything about the potential

revenue from this product if the PH 3 is good..

I see someone said BILLIONS.... I would be hesitant with this number and wait for
the company to give their projection

Note: given their CURRENT low revenue numbers, and the low activity/interest level,
I would expect this to get shorted post the announcement. Especially since I would
expect them to do a secondary offering to raise cash (dilution)

Disclaimer: I decided yesterday based on the 'low interest'/trading, to lock in the gains I had.
Yes, I might miss something, but if this pops on the open?? I wouldn't be slow to take at least
some of the gains you get. And if I am wrong, won't be the first time I mis-read something.

GOOD LUCK

Good morning. $JAGX

They will ask for extra shares, but not this week.

Great for the company. Most of us need to see $8 just to get back to the pre split price. When next offering ? Tomorrow after the blockbuster news ?

That's peanuts. That's a market cap of 87 million dollars, for a drug, unique on his market, in cancer therapy, with the potential of generating billions in revenue...

That's really low

I see 10 dollars incoming

Finally, we arrived to the day we have been waiting for since November 2023. I want to highlight 1 fact:
"Since all patient data will be included in the final locked database, we will remain blinded and will announce the comprehensive results of the full trial, including Stage II results, rather than proceeding with the original plan of announcing top line results for Stage I only.

So many patients chose to continue the treatment, that they couldn't have a intermediate data readout in november last year. SUPER BULLISH on those results. Don't forget that the primary endpoint are Patient Reported Outcomes (PRO's) GLTA

Well now we wait. Hopefully we wake up to good news.

with the SMALL number of shares outstanding, one would think good news could
lead to some upside movement.

But at the same time, those SHORT and holding onto their positions could put a damper
on things in a hurry IF there aren't a lot paying attention to the news

all going to hinge on what they say, how loud they say it, and IF the market is again, paying attention.

Its tried to move higher 2x today and got dragged down in response..

pick your reason.. See what it does into the close..

JAGX > IS A GREAT $$$$$ OPPORTUNITY.

Nice seeing the recent upside moves for the Jaguar.

Are expecting this to rockets assume postiviee results "?

Tomorrow morning is going to be one of those 'binary' events in the

baby bio tech world isn't it.